CLBS - カラドリアス・バイオサイエンス (Caladrius Biosciences Inc.) カラドリアス・バイオサイエンス

 CLBSのチャート


 CLBSの企業情報

symbol CLBS
会社名 Caladrius Biosciences Inc (カラドリアス・バイオサイエンス)
分野(sector) Health Care   ヘルスケア
産業(industry) Hospital/Nursing Management  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Caladrius Biosciences Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company''s lead product candidate CLBS03 is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient''s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study a Phase II prospective randomized placebo-controlled double-blind clinical trial to evaluate its Treg product candidate CLBS03 in adolescents with recent onset T1D. The Company plans to develop its product candidate CLBS12 in Japan which is an autologous therapy that derives its cells from peripheral blood through apheresis.   カラドリアス・バイオサイエンスは米国のバイオテクノロジ―企業。独自の細胞治療製品の開発に従事し、再生医療分野でのサ―ビスを提供する。虚血に対処するための治療法の開発、急性心筋梗塞後の損傷した心筋を治療、免疫系の不均衡によって引き起こされる疾患を治療、テクノロジ―再生医療プラットフォ―ムなどがある。   Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Its technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; OLOGO™ (formerly CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”).
本社所在地 106 Allen Road Fourth Floor Basking Ridge NJ 07920 USA
代表者氏名 David J. Mazzo デビットJ.マッツォ
代表者役職名 Chief Executive Officer Independent Director
電話番号 +1 908-842-0100
設立年月日 29465
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 221人
url https://www.caladrius.com/
nasdaq_url https://www.nasdaq.com/symbol/clbs
adr_tso
EBITDA EBITDA(百万ドル) -22.53046
終値(lastsale) 5.01
時価総額(marketcap) 48724464.42
時価総額 時価総額(百万ドル) 44.34802
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) -5.95137
当期純利益 当期純利益(百万ドル) 13.58047
決算概要 決算概要 BRIEF: For the 26 weeks ended 30 June 2018 Caladrius Biosciences Inc revenues was not reported. Net loss before extraordinary items increased 5% to $9.1M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.96 to -$0.95.

 CLBSのテクニカル分析


 CLBSのニュース

   Caladrius Biosciences, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:CLBS)  2022/05/06 21:11:49 Seeking Alpha
The following slide deck was published by Caladrius Biosciences, Inc.
   Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2022 Results - Earnings Call Transcript  2022/05/06 03:29:07 Seeking Alpha
Caladrius Biosciences, Inc. (NASDAQ:NASDAQ:CLBS) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants John Menditto - VP, Investor Relations & Corporate…
   CALADRIUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Caladrius Biosciences, Inc. - CLBS  2022/05/05 23:05:00 Wallstreet:Online
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Caladrius Biosciences, Inc. (NasdaqCM: CLBS) with Cend Therapeutics, Inc. pursuant to which Caladrius shareholders will end up owning just 50% of the combined company. KSF is seeking to determine whether the merger and the process that led
   Caladrius Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update  2022/05/05 20:05:00 GlobeNewswire
Signs definitive merger agreement with Cend Therapeutics along with immediate investment and collaboration agreements
   CALADRIUS BIOSCIENCES ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of CLBS and Encourages Investors to Contact the Firm  2022/05/02 17:08:00 GlobeNewswire
NEW YORK, May 02, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Caladrius Biosciences, Inc. (NASDAQ: CLBS) breached their fiduciary duties or violated the federal securities laws in connection with the company’s merger with Cend Therapeutics, Inc.
   Caladrius Biosciences Inc Shares Approach 52-Week Low - Market Mover  2021/12/30 04:50:13 Kwhen Finance
Caladrius Biosciences Inc (CLBS) shares closed today at 1.8% above its 52 week low of $0.81, giving the company a market cap of $50M. The stock is currently down 41.3% year-to-date, down 41.7% over the past 12 months, and down 70.6% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 71.3% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Industrials industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -419.1% The company's stock price performance over the past 12 months lags the peer average by -399.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Important Technical Indicators to watch: Palantir Technologies Inc. (NYSE:PLTR), Caladrius Biosciences, Inc. (NASDAQ:CLBS)  2021/12/12 23:28:45 Stock Equity
Palantir Technologies Inc. (NYSE:PLTR) with the stream of -1.41% also noticed, India Caladrius Biosciences, Inc. (NASDAQ:CLBS) encountered a rapid change of -1.16% in the last hour of Fridays trading session. The post Important Technical Indicators to watch: Palantir Technologies Inc. (NYSE:PLTR), Caladrius Biosciences, Inc. (NASDAQ:CLBS) appeared first on Stocks Equity .
   Vamping stocks: Sundial Growers Inc. (NASDAQ:SNDL -3.15%), Caladrius Biosciences, Inc. (NASDAQ:CLBS -1.96%)  2021/12/09 23:22:33 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Vamping stocks: Sundial Growers Inc. (NASDAQ:SNDL -3.15%), Caladrius Biosciences, Inc. (NASDAQ:CLBS -1.96%) appeared first on Stocks Equity .
   -$0.14 Earnings Per Share Expected for Caladrius Biosciences, Inc. (NASDAQ:CLBS) This Quarter  2021/12/04 10:04:43 Dakota Financial News
Brokerages expect that Caladrius Biosciences, Inc. (NASDAQ:CLBS) will report earnings of ($0.14) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Caladrius Biosciences earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.16). Caladrius Biosciences posted earnings per share []
   Traders cant brush off this: Castor Maritime Inc. (NASDAQ:CTRM), Caladrius Biosciences, Inc. (NASDAQ:CLBS)  2021/11/29 03:41:37 Stock Equity
Castor Maritime Inc. (CTRM) with the stream of -2.00% also noticed, India Caladrius Biosciences, Inc. (CLBS) encountered a rapid change of 0.00% in the last hour of trading session. Castor The post Traders cant brush off this: Castor Maritime Inc. (NASDAQ:CTRM), Caladrius Biosciences, Inc. (NASDAQ:CLBS) appeared first on Stocks Equity .
   Caladrius Biosciences Inc Shares Approach 52-Week Low - Market Mover  2021/12/30 04:50:13 Kwhen Finance
Caladrius Biosciences Inc (CLBS) shares closed today at 1.8% above its 52 week low of $0.81, giving the company a market cap of $50M. The stock is currently down 41.3% year-to-date, down 41.7% over the past 12 months, and down 70.6% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 71.3% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Industrials industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -419.1% The company's stock price performance over the past 12 months lags the peer average by -399.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Important Technical Indicators to watch: Palantir Technologies Inc. (NYSE:PLTR), Caladrius Biosciences, Inc. (NASDAQ:CLBS)  2021/12/12 23:28:45 Stock Equity
Palantir Technologies Inc. (NYSE:PLTR) with the stream of -1.41% also noticed, India Caladrius Biosciences, Inc. (NASDAQ:CLBS) encountered a rapid change of -1.16% in the last hour of Fridays trading session. The post Important Technical Indicators to watch: Palantir Technologies Inc. (NYSE:PLTR), Caladrius Biosciences, Inc. (NASDAQ:CLBS) appeared first on Stocks Equity .
   Vamping stocks: Sundial Growers Inc. (NASDAQ:SNDL -3.15%), Caladrius Biosciences, Inc. (NASDAQ:CLBS -1.96%)  2021/12/09 23:22:33 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Vamping stocks: Sundial Growers Inc. (NASDAQ:SNDL -3.15%), Caladrius Biosciences, Inc. (NASDAQ:CLBS -1.96%) appeared first on Stocks Equity .
   -$0.14 Earnings Per Share Expected for Caladrius Biosciences, Inc. (NASDAQ:CLBS) This Quarter  2021/12/04 10:04:43 Dakota Financial News
Brokerages expect that Caladrius Biosciences, Inc. (NASDAQ:CLBS) will report earnings of ($0.14) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Caladrius Biosciences earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.16). Caladrius Biosciences posted earnings per share []
   Traders cant brush off this: Castor Maritime Inc. (NASDAQ:CTRM), Caladrius Biosciences, Inc. (NASDAQ:CLBS)  2021/11/29 03:41:37 Stock Equity
Castor Maritime Inc. (CTRM) with the stream of -2.00% also noticed, India Caladrius Biosciences, Inc. (CLBS) encountered a rapid change of 0.00% in the last hour of trading session. Castor The post Traders cant brush off this: Castor Maritime Inc. (NASDAQ:CTRM), Caladrius Biosciences, Inc. (NASDAQ:CLBS) appeared first on Stocks Equity .

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 カラドリアス・バイオサイエンス CLBS Caladrius Biosciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)